Johnson & Johnson (JNJ)vsSight Sciences Inc (SGHT)
JNJ
Johnson & Johnson
$262.38
+0.78%
HEALTHCARE · Cap: $632.29B
SGHT
Sight Sciences Inc
$8.24
+1.23%
HEALTHCARE · Cap: $390.57M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 122999% more annual revenue ($97.93B vs $79.55M). JNJ leads profitability with a 21.5% profit margin vs -46.8%. JNJ earns a higher WallStSmart Score of 57/100 (C).
JNJ
Buy57
out of 100
Grade: C
SGHT
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-87.7%
Fair Value
$139.75
Current Price
$262.38
$122.63 premium
Margin of Safety
+27.7%
Fair Value
$7.65
Current Price
$8.24
$0.59 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
No standout strengths identified
Areas to Watch
Premium valuation, high expectations priced in
Expensive relative to growth rate
Earnings declined 0.9%
Trading at 8.2x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -69.1% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bull Case : SGHT
Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : SGHT
The primary concerns for SGHT are Price/Book, EPS Growth, Market Cap.
Key Dynamics to Monitor
JNJ profiles as a mature stock while SGHT is a turnaround play — different risk/reward profiles.
SGHT carries more volatility with a beta of 2.42 — expect wider price swings.
SGHT is growing revenue faster at 12.5% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 25/100), backed by strong 21.5% margins. SGHT offers better value entry with a 27.7% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Sight Sciences Inc
HEALTHCARE · MEDICAL DEVICES · USA
Sight Sciences Inc. (SGHT) is an innovative medical technology company specializing in the advancement of treatments for ocular diseases, with a particular emphasis on glaucoma management through both surgical and non-surgical approaches. The company’s diverse product portfolio, supported by a robust intellectual property framework, positions it favorably as demand for minimally invasive ophthalmic therapies escalates. By focusing on enhancing patient outcomes and refining its distribution network, Sight Sciences is set to capture significant market share in the evolving healthcare landscape, making it a noteworthy opportunity for institutional investors seeking growth in the medical technology sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?